What happened?
The Trump administration has launched Section 232 investigations into U.S. imports of pharmaceuticals and semiconductors, citing national security concerns. The probes, initiated on April 1, begin a 21-day public comment period and could lead to 10–25% tariffs. While smartphones and computers have been temporarily excluded, President Trump confirmed tariffs on chips will be announced next week. The move follows earlier tariffs on steel, aluminium, and autos, escalating trade tensions and impacting U.S. markets and economic forecasts.
Why it matters to India
India’s pharmaceutical and IT sectors could face indirect fallout if U.S. tariffs tighten global supply chains or trigger retaliatory trade measures. India exports both active pharmaceutical ingredients (APIs) and finished formulations to the U.S., and any shift in U.S. policy toward reshoring drug manufacturing could disrupt Indian pharma’s market access. Similarly, a redrawn global chip trade map could complicate India’s ambitions to emerge as a semiconductor hub amid ongoing efforts to attract chipmakers under the country’s PLI schemes.